Esperion Therapeutics (NASDAQ:ESPR) Reaches New 1-Year High – Still a Buy?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) reached a new 52-week high on Monday . The stock traded as high as $3.44 and last traded at $3.43, with a volume of 8108749 shares traded. The stock had previously closed at $2.80.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Wednesday, November 27th. Needham & Company LLC reduced their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Finally, StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Esperion Therapeutics Price Performance

The company has a 50 day moving average of $2.11 and a two-hundred day moving average of $2.16. The company has a market capitalization of $610.82 million, a PE ratio of -4.64 and a beta of 0.96.

Hedge Funds Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. BOKF NA purchased a new stake in shares of Esperion Therapeutics in the second quarter worth $26,000. Traphagen Investment Advisors LLC bought a new stake in Esperion Therapeutics during the 3rd quarter valued at about $27,000. Xponance Inc. bought a new position in shares of Esperion Therapeutics in the second quarter worth approximately $28,000. Sivia Capital Partners LLC purchased a new stake in shares of Esperion Therapeutics during the second quarter valued at approximately $44,000. Finally, National Bank of Canada FI increased its position in shares of Esperion Therapeutics by 115.9% during the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 10,225 shares in the last quarter. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.